Magnetar Financial LLC purchased a new stake in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The fund purchased 16,977 shares of the company's stock, valued at approximately $314,000. Magnetar Financial LLC owned approximately 0.06% of Fulgent Genetics at the end of the most recent reporting period.
Other hedge funds have also recently added to or reduced their stakes in the company. Intech Investment Management LLC raised its stake in Fulgent Genetics by 248.3% during the fourth quarter. Intech Investment Management LLC now owns 43,539 shares of the company's stock valued at $804,000 after buying an additional 31,037 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in Fulgent Genetics by 803.2% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 125,957 shares of the company's stock valued at $2,326,000 after acquiring an additional 112,011 shares during the last quarter. AlphaQuest LLC grew its stake in Fulgent Genetics by 314.7% in the fourth quarter. AlphaQuest LLC now owns 35,692 shares of the company's stock worth $659,000 after purchasing an additional 27,085 shares in the last quarter. Amundi lifted its holdings in Fulgent Genetics by 143.7% during the fourth quarter. Amundi now owns 8,816 shares of the company's stock worth $166,000 after buying an additional 5,199 shares during the period. Finally, Aigen Investment Management LP purchased a new stake in shares of Fulgent Genetics during the 4th quarter valued at $217,000. Institutional investors own 48.06% of the company's stock.
Fulgent Genetics Trading Down 0.3 %
Shares of FLGT traded down $0.05 during mid-day trading on Thursday, hitting $16.85. 355,634 shares of the company's stock were exchanged, compared to its average volume of 232,801. The business's 50 day moving average is $16.82 and its two-hundred day moving average is $18.73. Fulgent Genetics, Inc. has a fifty-two week low of $14.57 and a fifty-two week high of $25.11. The firm has a market capitalization of $519.47 million, a P/E ratio of -3.05 and a beta of 1.54.
Wall Street Analyst Weigh In
FLGT has been the topic of a number of recent research reports. StockNews.com upgraded Fulgent Genetics from a "sell" rating to a "hold" rating in a research note on Wednesday, March 5th. Piper Sandler reduced their target price on Fulgent Genetics from $22.00 to $16.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th.
View Our Latest Stock Analysis on FLGT
Insider Transactions at Fulgent Genetics
In related news, CFO Paul Kim purchased 100,000 shares of Fulgent Genetics stock in a transaction that occurred on Wednesday, March 5th. The shares were purchased at an average cost of $15.96 per share, with a total value of $1,596,000.00. Following the transaction, the chief financial officer now owns 348,282 shares of the company's stock, valued at approximately $5,558,580.72. The trade was a 40.28 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 31.76% of the company's stock.
About Fulgent Genetics
(
Free Report)
Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
Featured Stories
Before you consider Fulgent Genetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fulgent Genetics wasn't on the list.
While Fulgent Genetics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
